相关实验视频

Updated: Jul 11, 2025

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

以药物特定的定量抗Xa测定为指导的安德克萨尼特阿尔法剂量管理方案的表征

Holly T Lanham¹, Wassamon Viriyakitja², Mark Vestal³

¹Department of Pharmacy, Vanderbilt University Medical Center, 1211 Medical Center Drive, B131 VUH, Nashville, TN, 37232, USA. holly.t.lanham@vumc.org.

Journal of thrombosis and thrombolysis

|November 6, 2023

概括

在服用Xa因子抑制剂的患者中,安德克萨内特阿尔法推用于治疗出血. 虽然抗FXa选是有用的,但在本研究中,特定的药物测定显示出与生存结果的相关性很小.

科学领域:

药理学和治疗学药理学和治疗学
血液学血液学血液学
临床医学临床医学

背景情况:

安德克萨内特阿尔法是FDA批准的药物,并推用于治疗使用口服因子Xa (FXa) 抑制剂的患者的危及生命的出血.
安德克萨内特阿尔法的剂量取决于特定的FXa抑制剂,其剂量,以及自最后一次服用以来的时间.
机构协议通常包括抗FXa查和药物特异性检测,以指导随后的Andexanet alfa剂量.

研究的目的:

通过针对抗FXa和FXa抑制剂的特定测定来评估安德克萨内特α的使用情况.
评估测定结果与患者结局之间的关联,包括血栓事件和生存率.

主要方法:

追溯性,单中心研究分析安德克萨尼特阿尔法使用情况.
在抗FXa查和直接口服抗凝剂 (DOAC) 特定测定中收集的数据,以指导安德克萨内特阿尔法的使用.
二级终点包括血栓事件,住院时间,死亡率和出院处置.

主要成果:

大多数患者接受了阿皮克萨班治疗心房动和安德克萨尼特阿尔法治疗内出血逆转.
特定于DOAC的测定通常与最近已知的药物给药时间相关.
观察到DOAC特定测定水平与患者存活率之间存在很小的相关性;发生了9起血栓事件 (8.7%).

结论:

采集抗FXa测试屏幕是指导安德克萨尼特αα逆转的实际策略.
添加特定于DOAC的测定水平可能不会显著提高安德克萨内特阿尔法的临床效用.
需要进一步的研究才能充分理解特定测试在优化安德克萨尼特阿尔法治疗中的作用.

关键词:

安德克萨内特阿尔法这是一个反FXa屏幕.阿皮克萨班 (Apixaban) 是一种药物.在DOAC级别.在 DOAC 逆转的过程中.里瓦罗克萨班 (Rivaroxaban) 是一种药物.

更多相关视频

Conversion of a Capture ELISA to a Luminex xMAP Assay using a Multiplex Antibody Screening Method

Conversion of a Capture ELISA to a Luminex xMAP Assay using a Multiplex Antibody Screening Method

Published on: July 6, 2012

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Published on: September 10, 2018

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...